EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Abstract Background Despite the impressive anti-tumor activity of osimertinib in epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) patients, 30–40% of patients still show limited response. There is therefore a need to identify biomarkers that accurately predic...

Full description

Bibliographic Details
Main Authors: Qiufan Zheng, Shaodong Hong, Yan Huang, Hongyun Zhao, Yunpeng Yang, Xue Hou, Yuanyuan Zhao, Yuxiang Ma, Ting Zhou, Yaxiong Zhang, Wenfeng Fang, Li Zhang
Format: Article
Language:English
Published: Wiley 2020-02-01
Series:Clinical and Translational Medicine
Subjects:
T790M mutation
Allele frequency
Osimertinib
Non-small-cell lung cancer
Online Access:http://link.springer.com/article/10.1186/s40169-020-0269-y

Internet

http://link.springer.com/article/10.1186/s40169-020-0269-y

Similar Items